- BSc. Hon. Biochemistry – University of Saskatchewan (2010)
- MSc. Pharmacology & Neuroscience – Dalhousie University (2012)
- PhD Pharmacology – Dalhousie University (2016)
- Postdoctoral fellowship – The Scripps Research Institute, Florida (2017)
Dr. Laprairie is a member of the Drug Discovery and Development Research Group and the Cannabinoid Research Initiative of Saskatchewan (CRIS). He is a member of the Canadian Society for Pharmacology and Therapeutics (CSPT), the Canadian Consortium for the Investigators of Cannabinoids (CCIC), the American Society for Pharmacology and Experimental Therapeutics (ASPET), and the International Cannabinoids Research Society (ICRS).
Dr. Laprairie’s research focuses on the endocannabinoid system and specifically the type 1 cannabinoid receptor (CB1R). CB1R is activated by the body’s own cannabinoids, synthetic cannabinoids, and cannabinoids from marijuana (e.g. THC and cannabidiol). CB1R is a potential target for the regulation of appetite and the treatment of pain, spasticity in multiple sclerosis, Huntington’s disease, epilepsy, and anxiety, among others. Despite its potential as a therapeutic target, we are still learning how CB1R is regulated by cannabinoids to alter physiology. His laboratory is working to (1) understand how the many different cannabinoids from marijuana affect CB1R function; and (2) develop new compounds known as allosteric modulators that increase or decrease CB1R activity. Dr. Laprairie’s research utilizes molecular biology, cell culture and animal models to study the endocannabinoid system in an attempt to further our understanding of marijuana as a medicine, and possibly lead to the development of new drug compounds.
Hua T, Vemuri K, Nikas SP, Laprairie RB, Wu Y, Qu L, Pu M, Korde A, Jiang S, Ho JH, Han GW, Ding K, Li X, Liu H, Hanson MA, Zhao S, Bohn LM, Makriyannis A, Stevens RC, Liu ZJ (2017). Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature. doi: 10.1038/nature23272.
Bagher AM, Laprairie RB, Kelly MEM, Denovan-Wright EM (2013). Co-expression of the human cannabinoid receptor coding region splice variants (hCB1) affects the function of hCB1 receptor complexes. Eur J Pharmacol 721: 341-354.
Laprairie RB, Kelly MEM, Denovan-Wright EM (2013). Cannabinoids induce type 1 cannabinoid receptor expression in cell culture models of striatal neurons: implications for Huntington’s disease. Neuropharmacol 72: 47 – 57.
Laprairie RB, Kelly MEM, Denovan-Wright EM (2012). The dynamic nature of type 1 cannabinoid receptor (CB1) gene transcription. Br J Pharmacol 167: 1583-1595.
Hogel M, Laprairie RB, Denovan-Wright EM (2012). Promoters are differentially sensitive to N-terminal mutant huntingtin-mediated transcriptional repression. PLoS One 7: e411152.